AutoIVF, a company developing automated fertility care technology, has closed an equity investment round led by Vitrolife Group, with participation from Alpha Edison and other IVF industry investors.
AutoIVF’s flagship product, OvaReady, is an automated system designed to simplify egg retrieval and preparation in the IVF process. According to the company, the technology could support decentralizing egg retrieval procedures outside traditional IVF laboratory settings. Vitrolife Group, headquartered in Gothenburg, Sweden, is a global provider of medical devices and genetic testing solutions with 1,100 employees worldwide and a presence in over 125 countries.
“The National Institutes of Health’s ongoing support through their Small Business Innovation Research Awards has validated the strength of our technology and our rigorous clinical approach. This foundation has enabled us to demonstrate the real-world impact of OvaReady,” said Ravi Kapur, CEO of AutoIVF. “With this new investment and partnership, we’re excited to accelerate our path to market and explore collaborations that can expand access, scale innovation, and create lasting value across the reproductive health ecosystem.”
“This investment and partnership mark another step in our corporate strategy to build an end-to-end platform that connects products and services across the entire IVF workflow. By continuing to automate the IVF process we will enable safe, efficient and effective fertility care,” said Bronwyn Brophy O’Connor, CEO of the Vitrolife Group.
Erin Schardt, SVP and GM North America at Vitrolife Group, will join AutoIVF’s Board of Directors as part of the investment.
AutoIVF has raised over $16 million in public and private funding to date, including National Institute of Health SBIR awards. While the investment amount in this round was not disclosed, the funding is expected to help AutoIVF advance its mission to make fertility care more accessible, affordable, and efficient.
